LOW RISK MYELODYSPLASTIC SYNDROMES
Clinical trials for LOW RISK MYELODYSPLASTIC SYNDROMES explained in plain language.
Never miss a new study
Get alerted when new LOW RISK MYELODYSPLASTIC SYNDROMES trials appear
Sign up with your email to follow new studies for LOW RISK MYELODYSPLASTIC SYNDROMES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug R289 offers hope for blood disorder patients who failed other therapies
Disease control Recruiting nowThis study tests an experimental drug called R289 in about 86 adults with a type of blood cancer called lower-risk myelodysplastic syndromes (MDS). Participants must have tried other standard treatments without success. The main goal is to check the drug's safety and side effects…
Matched conditions: LOW RISK MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a Centuries-Old poison become a new weapon against a blood disorder?
Disease control Recruiting nowThis early-stage trial is testing whether an oral form of arsenic trioxide can safely help people with low-risk myelodysplastic syndromes (MDS) who have not improved with standard treatments. The study will first find the safest dose, then check how well it works after several cy…
Matched conditions: LOW RISK MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC